Unrelated cord blood transplantation for thalassaemia: A single-institution experience of 35 patients

T. H. Jaing, I. J. Hung, C. P. Yang, S. H. Chen, H. T. Chung, P. K. Tsay, Y. C. Wen

研究成果: 雜誌貢獻文章

38 引文 斯高帕斯(Scopus)

摘要

Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with β-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n=8), 5/6 (n=16), 4/6 (n=27), or 3/6 (n=1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34+ cells infused was 7.8 × 107/kg (range, 2.8-14.7 × 107/kg) and 4.0 × 105/kg (range, 1.7-19.9 × 105/kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9%, respectively. The cumulative incidence of TRM at 2 years was 11.7%. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score ≥80% achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLA-compatible sibling but who have well-matched unrelated donors should also be considered for CBT.

原文英語
頁(從 - 到)33-39
頁數7
期刊Bone Marrow Transplantation
47
發行號1
DOIs
出版狀態已發佈 - 一月 2012
對外發佈Yes

    指紋

ASJC Scopus subject areas

  • Hematology
  • Transplantation

引用此